Peptide 'glow up' claims on TikTok: what the science actually supports

What did @harms.peps actually say?

The creator pitched three peptides as a cosmetic and body composition stack: GHK-Cu for skin, hair, and nails; growth hormone-releasing peptides (CJC, and what sounds like ipamorelin or similar) for muscle and recovery; and "reda" (almost certainly retatrutide) as a triple-mechanism fat loss peptide. The closing line, "this is not medical advice and is for research purposes only," is a common disclaimer that does not change the practical effect of the recommendations being made.

The video is light on mechanism and completely silent on dosing, sourcing, risk, or regulatory status. Claims like "they will definitely improve your look" are presented as settled fact rather than as outcomes from early-stage or preclinical research.

Does the science back this up?

Partially, and the degree varies a lot by peptide. GHK-Cu has the most published human-adjacent data. Retatrutide has legitimate Phase 2 trial data behind it. The growth hormone secretagogue claims are the weakest of the three in terms of direct cosmetic evidence.

GHK-Cu (copper tripeptide) has demonstrated collagen-stimulating and antioxidant activity in cell culture and some small human studies. Pickart and Margolina (2018, Cosmetics) reviewed its skin remodeling activity and noted consistent signals in wound healing and collagen synthesis. That said, most studies use topical application, not injectable peptide, and effect sizes in humans are modest.

Retatrutide is a GIP, GLP-1, and glucagon triple-receptor agonist currently in Phase 2 trials. Jastreboff et al. (2023, NEJM) reported up to 24% body weight reduction over 48 weeks in adults with obesity. Describing it as hitting "fat loss at three different angles" is a rough but not entirely wrong description of its tri-agonist mechanism. What the creator skips: this drug is not approved, not available as a legitimate compounded peptide, and sourced entirely from unregulated grey-market labs.

The growth hormone peptide claims are the loosest. Increased GH pulse amplitude from secretagogues does not automatically translate to the cosmetic tightness outcomes described.

What did they get wrong (or right)?

They got the broad category right on retatrutide: it does have the most impressive clinical weight loss data of any peptide currently in trials. Credit where it is due. The GHK-Cu collagen claim is also directionally accurate, though overstated for systemic injectable use versus topical.

What they got wrong is significant. "They will definitely improve your look" is not supported by any controlled evidence for this specific stack used together. Stacking a GH secretagogue with a potent tri-agonist receptor agonist is not a tested or approved combination, and presenting it as a routine optimization protocol is irresponsible.

The "not medical advice" disclaimer while naming specific compounds and outcomes is a legal fig leaf, not a genuine safety caveat. The creator also mispronounces or misnames several peptides, which raises real questions about sourcing literacy. "Nipam" and "Mirelin" do not correspond to established peptide names, suggesting either audio issues or shallow familiarity with the compounds being recommended.

What should you actually know?

Retatrutide is not approved by the FDA for any indication. It exists in commercial grey markets as an unverified research chemical, with no quality control, no established human dosing protocol, and no long-term safety data outside the closely monitored Phase 2 trial setting. The Jastreboff 2023 NEJM data is real and genuinely exciting, but it was generated in a clinical trial with strict screening, medical supervision, and standardized pharmaceutical-grade compound. What you buy from a peptide vendor is not that.

GHK-Cu has a reasonable safety profile in topical use. Systemic injectable GHK-Cu has far less human data. Injecting anything from an unregulated supplier carries contamination, sterility, and dosing risks that no disclaimer erases.

Growth hormone secretagogues like CJC-1295 and ipamorelin are not approved drugs in the US. They have been removed from the FDA's list of permissible compounded substances. Anyone selling them as compounded medications is operating outside current regulatory guidance.

• Always ask where a peptide is sourced before considering any use.
• "Research purposes only" does not make an unapproved injectable safe to self-administer.
• Phase 2 trial results for retatrutide are real, but those results came from pharmaceutical-grade drug in supervised settings, not grey-market vials.